Lotus Pharmaceuticals, Inc. (LTUS) Receives Phase I Approval for Asthma Drug – International Business Times

Lotus Pharmaceuticals, Inc. (LTUS) Receives Phase I Approval for Asthma Drug
International Business Times
Lotus Pharmaceuticals, Inc. said that research conducted by a third party indicated that the Asthma market in China is approximately $300 million annually,
Lotus Pharmaceuticals Receives SFDA Approval to Initiate Phase I Clinical PR Newswire (press release)

all 12 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *